Abstract: Provided are a water-soluble Pd(II) complex, a synthesis method thereof and use thereof as a catalytic precursor. The complex has a chemical name, ammonium dinitrooxalato palladium (II), and a molecular formula of (NH4)2[Pd(NO2)2(C2O4)]·nH2O (n is the number of crystal water). The Pd(II) complex is synthesized by using PdCl2 or [Pd(NH3)2Cl2] as a starting material which is firstly converted into [Pd(NH3)4]Cl2 in ammonium hydroxide, followed by a chemical reaction between [Pd(NH3)4]Cl2 and excessive NaNO2 to produce trans-[Pd(NH3)2(NO2)2] via ligand substitution mechanism, and finally dissolving trans-[Pd(NH3)2(NO2)2] in an aqueous solution of oxalic acid leads to the formation of the target product (NH4)2[Pd(NO2)2(C2O4)]·2H2O. The complex does not contain chlorine and other elements that are harmful to a catalyst, is readily soluble in water and has a low thermal decomposition temperature.

Abstract: The present disclosure relates generally to methods for sensitizing PRC2 mutant tumors to immune checkpoint blockade therapy in a subject in need thereof comprising administering to the subject an effective amount of inactivated modified vaccinia virus Ankara (MVA) or MVA ?E3L.

Abstract: The present disclosure generally relates to printed circuit boards or printed circuit board assemblies for fiber optic communications. In one non-limiting embodiment, a method of assembling an optoelectronic assembly includes providing a printed circuit board with a first metal coating and an optical component with a second metal coating. The method further includes positioning the optical component relative to the printed circuit board with at least some portion of the first metal coating aligned with or adjacent to at least some portion of the second metal coating, and applying solder between the first metal coating and the second metal coating to couple the optical component and the printed circuit board.

Abstract: The present disclosure generally relates to printed circuit boards or printed circuit board assemblies for fiber optic communications. In one non-limiting embodiment, a method of assembling an optoelectronic assembly includes providing a printed circuit board with a first metal coating and an optical component with a second metal coating. The method further includes positioning the optical component relative to the printed circuit board with at least some portion of the first metal coating aligned with or adjacent to at least some portion of the second metal coating, and applying solder between the first metal coating and the second metal coating to couple the optical component and the printed circuit board.

Abstract: Provided in the invention is an SCR system urea mixer. The SCR system urea mixer comprises an outer pipe and an inner pipe arranged in the outer pipe. The outer pipe comprises an air inlet cone pipe (11) and an air inlet straight pipe (12) connected with the air inlet cone pipe (11). The inner pipe comprises an air inlet rectifying pipe (21) and a porous pipe (22). The porous pipe (22) is sleeved outside the air inlet rectifying pipe (21). The air inlet rectifying pipe (21) is provided with an airstream rotating mechanism (211), and the airstream rotating mechanism (211) is used for rotating exhaust gas which enters into the air inlet cone pipe (11). A rotating structure and a porous structure are used in the SCR system urea mixer, so that urea and engine exhaust are fully mixed; and the SCR system urea mixer is provided with heat preservation measures to prevent the crystallization of the urea.

Abstract: The present invention belongs to the field of genetic engineering drugs, and provides a mutein MuR6S4TR of TRAIL, and a preparation method and use thereof. The N-terminal positions 2-11 of the amino acid sequence of the mutein consist of the transmembrane peptide sequence RRRRRR (R6) and the binding sequence AVPI of the apoptosis inhibitor XIAP, the positions 12-169 are the TRAIL protein peptide segment (124-281 aa), and the specific sequence is as shown in SEQ ID NO: 2.

Abstract: The present invention belongs to the field of genetic engineering drugs, and provides a mutein MuR5S4TR of TRAIL, and a preparation method and use thereof. The N-terminal positions 2-10 of the amino acid sequence of the mutein consist of the transmembrane peptide sequence RRRRR (R5) and the binding sequence AVPI of the apoptosis inhibitor XIAP, the positions 11-169 are the TRAIL protein peptide segment (123-281 aa), and the specific sequence is as shown in SEQ ID NO: 2.

Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR6 and a preparation method and the application thereof. The amino acid sequence of the mutant is SEQ ID NO: 2. The mutant selectively transforms the amino acid coding sequence of No. 114-119 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERGP to RRRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence, glycine into arginine on the 118th coding sequence and proline into arginine on the 119th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of six arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.

Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR5 and a preparation method and the application thereof. The amino acid sequence of said mutant is SEQ ID NO: 2. The TRAIL CPPs-like mutant selectively transforms the amino acid coding sequence of No. 114-118 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERG to RRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence and glycine into arginine on the 118th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of five arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL CPPs-like mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.

Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR6 and a preparation method and the application thereof. The amino acid sequence of the mutant is SEQ ID NO: 2. The mutant selectively transforms the amino acid coding sequence of No. 114-119 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERGP to RRRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence, glycine into arginine on the 118th coding sequence and proline into arginine on the 119th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of six arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.

Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR5 and a preparation method and the application thereof. The amino acid sequence of said mutant is SEQ ID NO: 2. The TRAIL CPPs-like mutant selectively transforms the amino acid coding sequence of No. 114-118 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERG to RRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence and glycine into arginine on the 118th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of five arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL CPPs-like mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.

Abstract: The invention mainly relates to the field of genetic engineering drugs, in particular to a mutant cDNA sequence obtained by mutating valine at position 114, glutamate at position 116, glycine at position 118, proline at position 119 and glutamine at position 120 in an amino acid sequence at positions 114-281 of an extracellular fragment of a wild-type TRAIL protein respectively into arginines, so as to allow amino acids at positions 114-121 of the TRAIL protein to form a 8-consecutive arginine sequence, and then by gene synthesis and PCR mutation and splicing; and the TRAIL mutant has excellent therapeutic effect for a variety of tumors of different types, and is a new generation of promising drug for highly efficiently inducing tumor cell apoptosis.

Abstract: The invention has made public a cell phone biological microscope and a remote biological assay method. It includes lens cone. It also includes fixed glass slide component and active glass slide component; fixed glass slide component includes fixed glass slide stand and fixed glass slide; active glass slide component includes fixed support, active glass slide stand and active glass slide, where one end of fixed support is connected to the outer wall of lens cone, and the other end of the fixed support is flexibly connected to the said active glass slide stand. The invention has the benefits as follows: it provides a portable and user-friendly cell phone biological microscope and a remote biological assay method using this biological microscope. This cell phone biological microscope is equipped with an adjustable glass slide system to achieve the remote assay of biological sample.

Abstract: A cell phone microscope system, including lens and lens-clamping fixture. The lens-clamping fixture is equipped with a mounting hole, and the lens is mounted in the hole. The lens at least includes two pieces of glued lens. The glued lens is plated with anti-reflective film, and there is a lens aperture between the two pieces of glued lens. The cell phone microscope system is characterized by realistic imaging, large depth of field, clear imaging and convenient focusing.

Abstract: The invention mainly relates to the field of genetic engineering drugs, in particular to a mutant cDNA sequence obtained by mutating valine at position 114, glutamate at position 116, glycine at position 118, proline at position 119 and glutamine at position 120 in an amino acid sequence at positions 114-281 of an extracellular fragment of a wild-type TRAIL protein respectively into arginines, so as to allow amino acids at positions 114-121 of the TRAIL protein to form a 8-consecutive arginine sequence, and then by gene synthesis and PCR mutation and splicing; and the TRAIL mutant has excellent therapeutic effect for a variety of tumors of different types, and is a new generation of promising drug for highly efficiently inducing tumor cell apoptosis.